NEW YORK/WINNIPEG (Reuters) - Valeant Pharmaceuticals International Inc is abandoning its growth-by-acquisitions strategy for the time being to try to reduce debt, boost its stock price and one day return to its traditional deal-making in a stronger position, people familiar with the matter told Reuters.

from Reuters: Business News http://ift.tt/1w8krfe
from Reuters: Business News http://ift.tt/1w8krfe
Tidak ada komentar:
Posting Komentar